New York, June 27, 2024 - PRISM MarketView - Shares in Quoin Pharmaceuticals (Nasdaq: QNRX) climbed in morning trading on Thursday after the company announced that it will expand its two ongoing clinical trials to include international patients. The specialty pharmaceutical company said that its first international trial site will be opened at a research hospital in Saudi Arabia. Quoin is conducting two studies under an open Investigational New Drug Application (IND), evaluating QRX003 as a treatment for the rare genetic disease, Netherton Syndrome (NS).
Quoin has engaged an experienced local Clinical Research Organization to manage the study locally.
The company said in a statement that the new clinical site is currently treating a number of NS patients who will now become eligible for recruitment into Quoin’s studies. Plans to open additional international clinical sites are at an advanced stage.
"We are very pleased to announce this exciting development for our ongoing clinical studies. We hope that the opening of this first international site, which is currently treating Netherton patients, will speed up overall recruitment into our studies whilst expanding the diversity of the patient population being tested. We are working hard to open additional international sites to augment the five sites that are currently open in the US. Quoin is committed to completing recruitment into our clinical studies as expeditiously as possible with a view to potentially delivering the first approved treatment to this underserved patient population.”
Quoin CEO, Dr. Michael Myers
In March 2024, Quoin received FDA clearance to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises five products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities